- Prescribing Advice for GPs - https://www.prescriber.org.uk -

NICE Guidance - February 2022

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2022. This month there is one guideline that impacts upon primary care.

The Type 2 diabetes in adults: management guideline has been updated. The update reviewed the evidence on drug treatment and made new recommendations. The new recommendations place SGLT2 inhibitors earlier in drug treatment for patients with established atherosclerotic cardiovascular disease and heart failure. It is specifically recommended to offer an SGLT2 inhibitor with proven cardiovascular benefit in addition to metformin to such patients. It is also recommended to consider this intervention in patients at high risk of CVD characterised as a QRISK2 ≥ 10%. In patients who do not meet either of these criteria, SGLT2 inhibitors remains a second line treatment option along with DPP‑4 inhibitors, pioglitazone and sulfonylureas.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.